X4 Pharmaceuticals Receives U.S. FDA Fast Track Status for Mavorixafor in Chronic Neutropenia
Wednesday, June 11, 2025
X4 Pharmaceuticals has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational treatment, mavorixafor, aimed at chronic neutropenia (CN). Mavorixafor is an oral CXCR4 antagonist currently being studied in a global Phase 3 clinical trial, known as 4WARD, for certain primary CN conditions.
This latest designation builds on the earlier Fast Track status awarded to mavorixafor for WHIM syndrome, a rare immune disorder. The treatment was approved by the FDA in April 2024 for that indication.
At present, granulocyte-colony stimulating factor (G-CSF) is the only FDA-approved treatment for CN. Introduced in the 1990s, G-CSF is administered by injection and may lead to side effects such as bone pain, enlarged spleen, low platelet count, kidney and blood vessel inflammation, and bone loss. Long-term use, especially at higher doses, has been linked to a greater risk of developing leukaemia in patients with congenital neutropenia. These concerns often limit dosing, affecting treatment outcomes.
X4 Pharmaceuticals suggests that mavorixafor, taken orally, could offer a more manageable treatment option, balancing disease control with reduced treatment burden.
The FDA’s Fast Track programme is intended to support the quicker development and review of new treatments for serious conditions where there is an unmet medical need.
Source: globenewswire.com
